2 Growth Stocks to Buy in November Without Any Hesitation
Key PointsVertex Pharmaceuticals' core business remains healthy, and it has a portfolio of kidney disease candidates that could top $10 billion in annual sales.
2 biotech stocks to add to your portfolio this November are Vertex Pharmaceuticals and Regeneron. Both companies have shown strong growth this year, despite a slow start to 2026. Vertex recently received approval for a new drug called povetacicept, which is expected to be approved by the end of November. This medicine could diversify Vertex's revenue streams beyond its dominant cystic fibrosis (CF) products.
Regeneron also has an attractive pipeline, including the highly successful Dupixent for eczema and a newer higher-dose formulation of its Eylea eye medicine. Both stocks appear to have strong potential for growth, making them solid options to consider adding to your portfolio in November.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.